Public Offering Hunters

[starbuxsux]

$BOX - Box making final IPO updates
Summary:UPDATED: The enterprise cloud company will begin trading its shares on the New York Stock Exchange after the opening bell on Friday under the ticker symbol "BOX."

By Rachel King for Between the Lines | January 22, 2015 -- 21:09 GMT (21:09 GMT)

Box is making the final tweaks to its initial public offering paperwork.

In the fourth amendment to its S-1 filing with the U.S. Securities and Exchange Commission, Box reiterated it would be releasing 12.5 million shares of Class A common stock to the public market.

Final pricing is expected to follow later on Thursday.

The enterprise cloud company will begin trading its shares on the New York Stock Exchange after the opening bell on Friday under the ticker symbol "BOX."

The update falls roughly in line with Box's expectations earlier this year, previously projecting it would offer 14.4 million shares between the price of $11 and $13 a share with the aim to raise up to $186.9 million.

"The assumed initial public offering price of $12.00 per share, which is the midpoint of the estimated offering price range set forth on the cover page of this prospectus, is substantially higher than the pro forma net tangible book value per share of our outstanding capital stock upon the completion of this offering," according to the most recent document.

Morgan Stanley, Credit Suisse and J.P. Morgan have been enlisted as the lead underwriters.

Box first submitted its S-1 to the SEC last March. Describing itself as "emerging growth company," Box first filed privately thanks to a special rule under the Jumpstart Our Businesses (JOBS) Act, which stipulates a company seeking to go public can file confidentially if it is valued at less than $1 billion.

Yet once revealed, some of the financials prompted some criticism over severe losses matched by high spending rates.

According to the paperwork, revenue climbed 111 percent year-over-year to $124.2 million by the end of January 2014.

But Box also sustained losses of $50.3 million, $112.6 million and $168.6 million year-over-year for the 12-month time frames ending December 31, 2011, January 31, 2013 and 2014, respectively.

Nevertheless, the Los Altos, Calif-based company has been trying to prove its value and battling criticism since launching in 2004, starting with simply justifying the cloud storage element as an easier (and more secure) replacement to the USB thumb drive.

More recently, tech industry analysts and competitors alike have been debating if Box's delayed IPO was a rare demonstration of patience in a vertical that can't seem to slow down - or rather a case of too little, too late.

Opening days on Wall Street are often polarizing in the sense that they're typically viewed as either smashing or disappointing.

However, the following initial months can be volatile as well. Based on the near-microscopic attention Box has experienced since announcing plans to go public last March, 2015 could likely be much more tumultuous.

UPDATE: Box is reportedly setting its IPO at $14 per share, above expectations, according to an underwriter at Morgan Stanley, based on multiple reports on Thursday evening.

http://www.zdnet.com/article/box-prices-shares-ipo-nyse-wall-street/

[starbuxsux]

$SHAK - Shake Shack valuation could hit $500M
Company prices public offering at $14 to $16 per share
Jan 20, 2015 Jonathan Maze



Shake Shack Inc. priced shares Tuesday for its upcoming initial public offering at $14 to $16, an amount that would give the New York City-based burger chain a valuation of more than $500 million before trading even begins.

If the company’s stock trades at the top of that range, Shake Shack would raise $80 million in its IPO and have a valuation of $568 million, based on the company’s SEC documents.

Shake Shack’s IPO price could go even higher than that, given the amount of attention being paid to the offering, as well as the chain’s New York home and its predicted unit volumes of $2.8 million to $3.2 million, which is high for a fast-casual chain.

Growth concepts such as Shake Shack have received strong valuations in their initial public offerings in the past few years. Restaurant IPOs have averaged first-day increases of nearly 70 percent the past two years. Excluding the two weakest performers during that time, the average increase was 93 percent. Three growth chains, Noodles & Company, Potbelly Corp. and The Habit Restaurants Inc., have seen their stock prices more than double on their offerings.

Shake Shack appears well on its way toward a valuation north of $1 billion. If its price initially trades at the peak of its offering range and then doubles on its first day, the burger chain — which had just seven locations as recently as 2010 — would have a valuation of more than $1 billion.

Shake Shack has grown since then due to the increasing popularity of better-burger concepts and the chain’s outsized reputation. Restaurateur Danny Meyer’s Union Square Hospitality Group LLC started the concept as a hot dog cart in New York City’s Madison Square Park in 2001. The first location opened in 2004.

The company has since grown to 63 units, 36 of which are in the U.S. and 27 international, with systemwide sales of $140 million in 2013. The company has average unit volumes of $5 million, including $7.4 million in Manhattan, but expects those to ease to $2.8 million to $3.2 million over time.

The company reported $83.8 million in revenue in the first three quarters of 2014, according to SEC documents, a 41-percent increase over the same period a year ago.

Shake Shack will trade on the New York Stock Exchange under the symbol SHAK. After the IPO, the company will be separate from the privately held Union Square Hospitality Group.

In addition to Union Square Hospitality Group, Shake Shack’s sponsors include the private-equity firm Leonard Green & Partners and the hedge fund Select Equity Group.

J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC are acting as joint lead book-running managers for the offering. Barclays Capital Inc., Goldman Sachs & Co., and Jefferies LLC are also acting as book-running managers, while William Blair & Company LLC and Stifel are co-managers.

Contact Jonathan Maze at [e-mail].
Follow him on Twitter: @jonathanmaze

[starbuxsux]

$XON - XON Prices Offering At $27/Share

1/22/2015 3:46 AM ET

Intrexon Corp. (XON: Quote) is selling 3.75 million shares of its common stock to the public at a price of $27.00 each. The underwriters have a 30-day option to purchase up to an additional 562,500 shares of common stock offered in the public offering.

Last week, Intrexon and its oncology partner, ZIOPHARM Oncology (ZIOP) entered into a broad exclusive licensing agreement with The University of Texas MD Anderson Cancer Center for CAR T (chimeric antigen receptor T) Cell, TCR (T-cell receptor), NK (Natural killer) Cell programs and associated technologies for the development of non-viral adoptive cellular therapies. The company expects up to five CARs to enter the clinic in 2015.

Intrexon in partnership with Fibrocell Science Inc. (FCSC) is developing a cell-based therapeutic GM-HDF-COL7 for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), the most severe form of the rare connective tissue disorder epidermolysis bullosa. The companies plan to file an investigational new drug application with the FDA in the first half of 2015 for GM-HDF-COL7.

The offering is expected to generate proceeds of approximately $101.25 million, and is scheduled to close on January 27, 2015.

XON closed Wednesday's trading at $28.40, down 12.32%.

by RTT Staff Writer

For comments and feedback: [e-mail]

[starbuxsux]

$RDUS - Radius Health, Inc. Announces Proposed Public Offering

WALTHAM, Mass., Jan. 20, 2015 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS) (the "Company"), a science-driven biopharmaceutical company focused on developing new therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases, including hormone responsive cancers, today announced that it is commencing an underwritten registered public offering of 3,500,000 shares of its common stock. The Company also expects to grant the underwriters an option to purchase up to an additional 525,000 shares of its common stock, exercisable for 30 days. All of the shares in the proposed offering are to be sold by the Company. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Goldman, Sachs & Co. and BofA Merrill Lynch are acting as joint book-running managers for the offering. Cowen and Company is acting as lead manager.

The offering is being made pursuant to an effective shelf registration statement on Form S-3 filed with the Securities and Exchange Commission on January 20, 2015. This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of shares of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

A preliminary prospectus supplement describing the terms of the offering will be filed with the Securities and Exchange Commission and will form a part of the effective registration statement. Copies of the preliminary prospectus supplement and accompanying prospectus relating to the offering may be obtained, when available, by contacting Goldman, Sachs & Co., Attention: Prospectus Department, 200 West Street, New York, New York 10282, or by telephone at [phone] or e-mail at [e-mail], or BofA Merrill Lynch, 222 Broadway, New York, NY 10038, Attn: Prospectus Department, or via email, at [e-mail].

Investor Relations
Barbara Ryan
Investor Relations
Radius Health, Inc.
203-274-2825
- See more at: http://globenewswire.com/news-release/2015/01/20/698678/10116238/en/Radius-Health-Inc-Announces-Proposed-Public-Offering.html#sthash.kc2RD1Ok.dpuf

[starbuxsux]

$ARNA - Arena Pharmaceuticals Announces Public Offering of Common Stock

4:04 PM ET 1/20/15 | PR Newswire

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares are being offered by Arena.

Jefferies LLC and Piper Jaffray & Co. are acting as joint book-running managers for the offering.

A registration statement relating to the shares described above was previously filed with the Securities and Exchange Commission (SEC) and is effective. A preliminary prospectus supplement related to the offering will be filed with the SEC and will be available on the SEC's website located at http://www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to this offering, when available, may be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 12th Floor, New York, NY 10022, by telephone at [phone], or by e-mail at [e-mail]; or Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, Suite 800, Minneapolis, MN 55402, by telephone at [phone], or by email at [e-mail].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Arena Pharmaceuticals

Arena is embracing the challenge of improving health by seeking to bring innovative medicines targeting G protein-coupled receptors to patients. Arena's internally discovered drug, BELVIQ(R) (lorcaserin HCl), is approved in the United States, and Arena is focused on discovering, developing and commercializing additional drugs to address unmet medical needs. Arena's US operations are located in San Diego, California, and its operations outside of the United States, including its commercial manufacturing facility, are located in Zofingen, Switzerland.

Arena Pharmaceuticals(R) and Arena(R) are registered service marks of Arena Pharmaceuticals, Inc. BELVIQ(R) is a registered trademark of Arena Pharmaceuticals GmbH.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Arena's expectations with respect to the public offering; embracing the challenge of improving health; seeking to bring innovative medicines to patients; and Arena's focus, plans, goals, strategy, expectations, research and development programs, and ability to discover and develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the following: risks and uncertainties related to the public offering, including the satisfaction of customary closing conditions; risks related to commercializing drugs, including regulatory, manufacturing, supply and marketing issues and the availability and use of BELVIQ; cash and revenues generated from BELVIQ, including the impact of competition; Arena's revenues will be based in part on estimates, judgment and accounting policies, and incorrect estimates or disagreement regarding estimates or accounting policies may result in changes to Arena's guidance or previously reported results; the timing and outcome of regulatory review is uncertain, and BELVIQ may not be approved for marketing when expected or ever in combination with another drug, for another indication or using a different formulation or in any other territory for any indication; regulatory decisions in one territory may impact other regulatory decisions and Arena's business prospects; government and commercial reimbursement and pricing decisions; risks related to relying on collaborative arrangements; the timing and receipt of payments and fees, if any, from collaborators; the entry into or modification or termination of collaborative arrangements; unexpected or unfavorable new data; nonclinical and clinical data is voluminous and detailed, and regulatory agencies may interpret or weigh the importance of data differently and reach different conclusions than Arena or others, request additional information, have additional recommendations or change their guidance or requirements before or after approval; data and other information related to any of Arena's research and development may not meet regulatory requirements or otherwise be sufficient for (or Arena or a collaborator may not pursue) further research and development, regulatory review or approval or continued marketing; Arena's and third parties' intellectual property rights; the timing, success and cost of Arena's research and development; results of clinical trials and other studies are subject to different interpretations and may not be predictive of future results; clinical trials and other studies may not proceed at the time or in the manner expected or at all; having adequate funds; and satisfactory resolution of litigation or other disagreements with others. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

View data
Contact: Arena Pharmaceuticals, Inc. Media Contact: Russo Partners Craig M. Audet, Ph.D., Senior Vice President, David Schull, President Operations & Head of Global Regulatory Affairs [e-mail] [e-mail] 858.717.2310 858.453.7200, ext. 1612

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/arena-pharmaceuticals-announces-public-offering-of-common-stock-300023196.html

SOURCE Arena Pharmaceuticals, Inc.

[deadjim]

this one's trying to do something

[starbuxsux]

$AUY - Yamana Gold announces C$260.2 mln equity financing

6:06 AM ET 1/13/15 | Briefing.com

The co announced it entered into an agreement with a syndicate of underwriters under which the Underwriters agreed to buy on a bought deal basis by way of a short form prospectus, 49,100,000 common shares of Yamana at a price of C$5.30 per Share for gross proceeds of C$260,230,000. The net proceeds of the Offering will be used for general corporate purposes and to reduce the Company's debt.

[starbuxsux]

After Banner Year, IPO Parade Marches On

Jan 01, 2015 12:06:00 (ET)

By Telis Demos
The U.S. IPO market in 2014 enjoyed its best year in more than a decade, thanks in part to Alibaba Group Holding Ltd.'s record $25 billion debut. But given the lack of another blockbuster deal on the horizon, an anticipated interest-rate increase and the recent tumble in energy prices, some slowdown in 2015 looks inevitable.

Participants still believe the IPO market will remain strong, though, with money still pouring into equities and fresh offerings coming.

IPOs of companies listed in the U.S. raised $96 billion across 293 deals in 2014, according to Dealogic. Both figures were the highest since 2000, the crest of the dot-com frenzy, when 432 IPOs raised $105 billion.

An increase in interest rates, largely expected to arrive in the second half of 2015, could act as a headwind, as it could create more attractive alternatives to yield-oriented IPOs, such as those of real-estate investment trusts or natural resources partnerships that are required to pay out their earnings as dividends in order to avoid taxes.

Moreover, given the steep decline in prices for oil and gas, the energy sector in 2015 looks unlikely to match the $8.7 billion worth of IPOs it contributed the year before.

Nevertheless, both the supply and demand sides of the IPO market look strong, bankers argue. On the supply side, "the pipeline we have now is as strong as it was a year ago, if not stronger," said Evan Damast, global head of equity syndicate for Morgan Stanley.

Already, a handful of companies have filed for potential 2015 IPOs, including burger chain Shake Shack Inc., consumer lender OneMain Financial Holdings Inc., and chemicals distributor Univar Inc.

Mr. Damast said that on the demand side, the lack of a huge deal to attract investors could help other offerings. "Megadeals create a lot of headlines and interest. But the absence of one also means investors will need to look at 10 deals for the year, rather than two," said Mr. Damast.

He also said that investors who were putting more money to work in stocks generally would still see IPOs as a way to quickly build up big new positions. Investors overall plugged $37 billion into U.S.-based equity funds in the week ended Dec. 24, the largest weekly inflow recorded by Lipper since 1992. When these funds put money to work, they often buy into IPOs, rather than try to build up positions in existing public companies whose prices already have soared.

"New issues provide investors with quick liquidity in large size unlike the gradual pain of putting on new positions in the open market. That need isn't getting any smaller," he said.

And IPOs in 2014 again delivered share-price gains that beat the broader market, rising 18.9% from their offer price versus a gain of 11.4% in the S&P 500.

Among the biggest gainers was Alibaba, the Chinese e-commerce company, whose shares jumped 38% in first-day trading, and have gained a further 13% from there. Radius Health Inc., a maker of drugs for osteoporosis and other conditions, was the top-performing IPO in 2014, rising 375% from its offering in June through Tuesday.

"A lot of investors realized that on a fundamental basis [stock-market] valuations weren't stretched, so they started to put money to work again in new companies," said David Hermer, global head of equity capital markets at Credit Suisse Group AG. "Supply of IPOs won't be significantly down" in 2015, as long as the stock market itself remains strong, he said.

Some other deals' performance were more up-and-down, however. The two companies with the biggest first-day jumps in 2014, drug maker Dicerna Pharmaceuticals Inc. and health-care software firm Castlight Health Inc., which popped 207% and 149%, respectively, were up 7% and down 28%, respectively, through Tuesday.

Unlike in prior years, when market volatility led investors to abandon IPOs, offerings continued throughout 2014 despite periods of turbulence. Deals priced even during the most violent stock-market selloff in early October, when S&P 500 index dropped as much as 6%, and in early December, when it slipped 5%. Lending Club Corp., in December, and Dominion Midstream Partners LP, in October, jumped more than 25% in first-day trading during those periods.

Other sectors in 2015 could pick up slack from energy, including consumer-facing companies. For example, Virgin America Inc. was up 89%. Consumer product, restaurant and hotel IPOs--a group including camera maker GoPro Inc., and burger chain Habit Restaurants Inc.--outperformed all other sectors, gaining on average 57% from their offering price through year-end, according to Dealogic.

Biotechnology companies also will continue to hit the market, drawn by the strong performance of IPOs in 2014.

"Companies that are more growth-oriented and dependent on growth in U.S. economy will benefit from lower oil prices, so we'll see more activity there," said J.D. Moriarty, head of U.S. equity capital markets at Bank of America Merrill Lynch. That group includes consumer-products makers, retailers and some Internet companies. But "activity going on in energy is not going to be entirely replaced by consumer and retail."


Access Investor Kit for Credit Suisse Group AG

Visit http://www.companyspotlight.com/partner?cp_code=P479&isin=CH0012138530

Access Investor Kit for Credit Suisse Group AG

Visit http://www.companyspotlight.com/partner?cp_code=P479&isin=US2254011081

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

(END) Dow Jones Newswires

January 01, 2015 12:06 ET (17:06 GMT)


Copyright (c) 2015 Dow Jones & Company, Inc.

[JohnCM]

Jaw dropping fund raise recently was ANV issuing warrants upon purchase of shares at $1.00 offering a purchase price for a period of 5 years at a price of $1.10

Wow! Talk about a sweetener!!

[starbuxsux]

$SNGX - Soligenix Announces Closing of Public Offering of Units

9:23 AM ET 12/24/14 | PR Newswire

Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that on December 24, 2014 it closed its previously announced registered public offering.

The Company raised approximately $2.3 million in gross proceeds from the offering and intends to use the net proceeds from the offering to fund its research and development activities, including the conduct of a Phase 3 clinical trial of SGX301 (synthetic hypericin) for the treatment of cutaneous T-cell lymphoma, as well as for general working capital needs.

Roth Capital Partners acted as the sole book-running manager in this offering. H.C. Wainwright & Co. acted as co-manager in this offering.

The securities described above were offered pursuant to a Registration Statement on Form S-1 (File No. 333-199761), which was declared effective by the United States Securities and Exchange Commission ("SEC") on December 18, 2014. There will be no additional closings of the offering.

This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to their registration or qualification under the securities laws of any such state or jurisdiction.

About Soligenix, Inc.

Soligenix is a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense. Our BioTherapeutics business segment is developing SGX301 as a first-in-class photo-dynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma, proprietary formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation, including pediatric Crohn's disease (SGX203) and acute radiation enteritis (SGX201), and our novel innate defense regulator technology (SGX942) for the treatment of oral mucositis.

Our Vaccines/BioDefense business segment includes active development programs for RiVax(TM), our ricin toxin vaccine candidate, VeloThrax(TM), our anthrax vaccine candidate, OrbeShield(TM), our GI acute radiation syndrome therapeutic candidate and SGX101 and SGX943, our melioidosis therapeutic candidates. The development of our vaccine programs is supported by our heat stabilization technology, known as ThermoVax(TM), under existing and on-going government contract funding.

For further information regarding Soligenix, Inc., please visit the Company's website at www.soligenix.com.

This press release may contain forward-looking statements that reflect Soligenix, Inc.'s current expectations about its future results, performance, prospects and opportunities, including but not limited to statements relating to its product development programs, potential market sizes, patient populations and clinical trial enrollment and any other statements that are not historical facts. These forward-looking statements are often identified by words such as "anticipates," "estimates," "believes," "intends," "potential," or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual events or results in future periods to differ materially from what is expressed in, or implied by, these statements. Soligenix cannot assure you that it will be able to successfully develop, achieve regulatory approval for or commercialize products based on its technologies, particularly in light of the significant uncertainty inherent in developing vaccines against bioterror threats conducting preclinical and clinical trials of vaccines, obtaining regulatory approvals and manufacturing vaccines, that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that it will be able to successfully obtain any further funding to support product development and commercialization efforts, including grants and awards, maintain its existing grants which are subject to performance requirements, enter into any biodefense procurement contracts with the US Government or other countries, that it will be able to compete with larger and better financed competitors in the biotechnology industry, that changes in health care practice, third party reimbursement limitations and Federal and/or state health care reform initiatives will not negatively affect its business, or that the US Congress may not pass any legislation that would provide additional funding for the Project BioShield program. These and other risk factors are described from time to time in filings with the Securities and Exchange Commission, including, but not limited to, Soligenix's reports on Forms 10-Q and 10-K. Unless required by law, Soligenix assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/soligenix-announces-closing-of-public-offering-of-units-300013913.html

SOURCE Soligenix, Inc.

[starbuxsux]

$SNGX - Soligenix Announces Pricing of Public Offering of Units

8:24 AM ET 12/19/14 | PR Newswire

Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today the pricing of its registered public offering of 1,886,530 units at an offering price of $1.21 per unit, with each unit consisting of one share of common stock and 0.6 of a warrant to purchase one share of common stock. Each whole warrant will be immediately exercisable to purchase one share of common stock at an exercise price of $1.48 per share and will expire on the fifth anniversary of its issuance. Soligenix expects to receive gross proceeds of approximately $2.3 million from this offering, before deducting underwriting discounts, commissions and other related expenses. The closing of the offering is expected to occur on December 24, 2014, subject to the satisfaction of customary closing conditions.

The Company plans to use the net proceeds from the offering to fund its research and development activities, including the conduct of a Phase 3 clinical trial of SGX301 (synthetic hypericin) for the treatment of cutaneous T-cell lymphoma, as well as for general working capital needs.

Roth Capital Partners is acting as the sole book-running manager in this offering. H.C. Wainwright & Co. is acting as co-manager in this offering.

A registration statement on Form S-1 relating to this offering has been filed with the U.S. Securities and Exchange Commission and is effective. A preliminary prospectus relating to the offering has been filed with the SEC and is available on the SEC's website at www.sec.gov. Copies of the final prospectus relating to the offering, when available, may be obtained from Roth Capital Partners, LLC, 888 San Clemente Drive, Newport Beach, CA 92660, [phone], or from the above-mentioned SEC website.

This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to their registration or qualification under the securities laws of any such state or jurisdiction.

About Soligenix, Inc.

Soligenix is a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense. Our BioTherapeutics business segment is developing SGX301 as a first-in-class photo-dynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma, proprietary formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation, including pediatric Crohn's disease (SGX203) and acute radiation enteritis (SGX201), and our novel innate defense regulator technology (SGX942) for the treatment of oral mucositis.

Our Vaccines/BioDefense business segment includes active development programs for RiVax(TM), our ricin toxin vaccine candidate, VeloThrax(TM), our anthrax vaccine candidate, OrbeShield(TM), our GI acute radiation syndrome therapeutic candidate and SGX101 and SGX943, our melioidosis therapeutic candidates. The development of our vaccine programs is supported by our heat stabilization technology, known as ThermoVax(TM), under existing and on-going government contract funding.

This press release may contain forward-looking statements that reflect Soligenix, Inc.'s current expectations about its future results, performance, prospects and opportunities, including but not limited to statements relating to its product development programs, potential market sizes, patient populations and clinical trial enrollment and any other statements that are not historical facts. These forward-looking statements are often identified by words such as "anticipates," "estimates," "believes," "intends," "potential," or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual events or results in future periods to differ materially from what is expressed in, or implied by, these statements. Soligenix cannot assure you that it will be able to successfully develop, achieve regulatory approval for or commercialize products based on its technologies, particularly in light of the significant uncertainty inherent in developing vaccines against bioterror threats conducting preclinical and clinical trials of vaccines, obtaining regulatory approvals and manufacturing vaccines, that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that it will be able to successfully obtain any further funding to support product development and commercialization efforts, including grants and awards, maintain its existing grants which are subject to performance requirements, enter into any biodefense procurement contracts with the US Government or other countries, that it will be able to compete with larger and better financed competitors in the biotechnology industry, that changes in health care practice, third party reimbursement limitations and Federal and/or state health care reform initiatives will not negatively affect its business, or that the US Congress may not pass any legislation that would provide additional funding for the Project BioShield program. These and other risk factors are described from time to time in filings with the Securities and Exchange Commission, including, but not limited to, Soligenix's reports on Forms 10-Q and 10-K. Unless required by law, Soligenix assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.

www.soligenix.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/soligenix-announces-pricing-of-public-offering-of-units-300012443.html

SOURCE Soligenix, Inc.

[JohnCM]

Can we keep an eye out for this one?

CDx Life, a Science and Technology Company based in La Jolla, CA, has started taking pre-orders for MyDx - the world's first portable analyzer for everyone.

MyDx leverages technology developed by the Jet Propulsion Laboratory (JPL), used by Nasa and funded by the Bill & Melinda Gates Foundation for other applications. Acting as an electronic nose, MyDx is engineered to detect molecules in vapor.

The analyzer itself has a user friendly interface designed to easily communicate with any iOS or Android smartphone. Once the app is downloaded and the device is synced, a very small sample can be placed in the sample chamber, which is then heated to release the chemicals of interest into the vapor phase for detection.

Over the course of the next 24 months, the MyDx team will be rolling out the four different sensors, the first of which is the Canna Sensor - programmed to test for the presence of the most important compounds of interest in Cannabis, including THC and CBD. Using the associated App, MyDx will allow patients to track how each marijuana strain is making them feel or helping them relieve, based on the chemical composition of the plant, not the way it looks, smells or sounds.

"What people are inhaling today is more or less a black box," said Daniel Yazbeck, one of the financial backers of the project. MyDx is a device that will improve consumer's health and empower an industry with the science it deserves to achieve true and practical quality control."
MyDx has launched a campaign on the popular crowdfunding website Indiegogo.com, with an initial goal of pre-selling at least 100 devices in order to predict future demand. Everyone who donates $199.00 or more will save $200 of the projected retail price of $399, and will be the first to help define and receive MyDx before it hits the broader market.
The CDx team has created a product that complements the use of medical marijuana in order to help people in need, such as cancer patients. Consumers can finally learn and understand exactly what and how much they are putting in their bodies.

About CDx
CDx, Inc. was founded on the mission of empowering people to live healthier lives by understanding the purity of everything they eat, drink, and inhale. While CDx plans to ship MyDx globally, the team has made a strategic decision not to offer the cannabis application to customers in states that have not legalized the adult possession and consumption of cannabis either medically or recreationally.
MyDx - A Device for a Better Life

[JohnCM]

Sick ... but I would buy at 0.73 nevertheless.

Each whole warrant entitles the holder thereof to purchase one share of our common stock at an exercise price of US$1.10 for a period of five years from the closing date of the Offering.

[starbuxsux]

Allied Nevada Announces Closing of Previously Announced Public Offering of Common Stock and Warrants

1:45 PM ET 12/12/14 | Marketwired

Allied Nevada Gold Corp. ("Allied Nevada", "us", "we", "our" or the "Company") (TSX: ANV)(NYSE MKT: ANV) today announced that it has closed the previously announced public offering (the "Offering") of shares of common stock and warrants, and issued 21,750,000 shares and 10,875,000 warrants for gross proceeds of US$21,750,000. In connection with the purchase, investors received one share of our common stock and one half warrant to purchase our common stock for a price of US$1.00. Each whole warrant entitles the holder thereof to purchase one share of our common stock at an exercise price of US$1.10 for a period of five years from the closing date of the Offering. The warrants will not be separately listed for trading. H.C. Wainwright & Co., LLC acted as the sole lead placement agent for the offering in the United States and Canaccord Genuity Corp. acted as co-placement agent for the offering in Canada.

The Offering was conducted in the United States only by means of a prospectus supplement and an accompanying prospectus filed as part of an effective shelf registration statement filed with the Securities and Exchange Commission ("SEC") on Form S-3 (File No. 333-200357), which was declared effective by the SEC on November 25, 2014.

Additional details of the Company's business, finances, appointments and agreements, including the United States prospectus supplement mentioned above, can be found as part of the Company's continuous public disclosure as a reporting issuer with the SEC on EDGAR at www.sec.gov and filed with Canadian securities regulators on SEDAR at www.sedar.com. Alternatively, copies of the United States prospectus supplement can be obtained by request at H.C. Wainwright & Co., LLC by contacting by telephone at [phone] or by e-mail at [e-mail].

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor will there be any sale of these securities in any jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

Cautionary Statement Regarding Forward Looking Information

This press release contains forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended (the "Securities Act"), Section 21E of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") (and the equivalent under Canadian securities laws) and the Private Securities Litigation Reform Act (the "PSLRA") or in releases made by the U.S. Securities and Exchange Commission (the "SEC"), all as may be amended from time to time. This cautionary statement is being made pursuant to the Securities Act, the Exchange Act and the PSLRA with the intention of obtaining the benefit of the "safe harbor" provisions of such laws.

All statements, other than statements of historical fact, included herein or incorporated by reference, that address activities, events or developments that we expect or anticipate will or may occur in the future, are forward-looking statements. Generally, these forward-looking statements can be identified by the use of forward-looking terminology such as "estimate", "plan", "anticipate", "expect", "intend", "believe", "project", "target", "budget", "may", "can", "will", "would", "could", "should", "seeks", or "scheduled to", or other similar words, or negatives of these terms or other variations of these terms or comparable language or any discussion of strategy or intentions. Such forward-looking statements include, without limitation, statements regarding our future business strategy, plans and goals; risks relating to fluctuations in the price of gold and silver; uncertainties concerning reserve, resource and grade estimates; the availability and timing of capital for financing the Company's exploration, development and expansion activities; anticipated costs, anticipated production, anticipated sales, anticipated capital expenditures, project economics, net present values and expected rates of return; the realization of expansion and construction activities and the timing thereof; production estimates and other statements that are not historical facts. Forward-looking statements address activities, events or developments that Allied Nevada expects or anticipates will or may occur in the future, and are based on current expectations and assumptions. These statements involve known and unknown risks, uncertainties, assumptions and other factors which may cause our actual results, performance or achievements to be materially different from any results, performance or achievements expressed or implied by such forward-looking statements.

Important factors that could cause actual results, performance or achievements to differ materially from those in the forward-looking statements include, among others, risks relating to fluctuations in the price of gold and silver; uncertainties concerning reserve, resource and grade estimates; the availability and timing of capital for financing the Company's exploration, development and expansion activities; anticipated costs, anticipated production, anticipated sales, anticipated capital expenditures, project economics, net present values and expected rates of return; the realization of expansion and construction activities and the timing thereof; production estimates; as well as those factors discussed in Allied Nevada's filings with the SEC including Allied Nevada's latest Annual Report on Form 10-K and its other SEC filings (and Canadian filings) including, without limitation, its latest Quarterly Report on Form 10-Q (which may be secured from us, either directly or from our website at www.alliednevada.com or at the SEC website www.sec.gov). Although Allied Nevada has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those described in forward-looking statements, there may be other factors that cause results, performance or achievements not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results, performance and achievements and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. The Company does not intend to publicly update any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required under applicable securities laws.

Contacts:
Allied Nevada Gold Corp.
Randy Buffington
President & CEO
[phone]

Allied Nevada Gold Corp.
Tracey Thom
Vice President, Investor Relations
[phone]



SOURCE: Allied Nevada Gold Corp.

[starbuxsux]

Yep...and can you imagine with gold's inevitable recovery what a steal that's going to be?

[JohnCM]

Allow me a minute to digest this fact ...

Each whole warrant entitles the holder thereof to purchase one share of our common stock at an exercise price of $1.10 for a period of five years from the closing date of the Offering

[TheMotivatedTrader]

Right now, the Algos are attacking ANV and running it down (to be expected on an offering). Same thing is happening in another ticker I am in.

Algos will create some great buying opportunities.

[starbuxsux]

$ANV - Allied Nevada Announces Pricing of Public Offering of Common Stock and Warrants

8:09 AM ET 12/9/14 | Marketwired

Allied Nevada Gold Corp. ("Allied Nevada", "us", "we", "our" or the "Company") (TSX: ANV)(NYSE MKT: ANV) today announced that it has priced a public offering (the "Offering") of shares of common stock and warrants. In connection with the purchase, investors will receive one share of our common stock and one half warrant to purchase our common stock for a price of $1.00. Each whole warrant entitles the holder thereof to purchase one share of our common stock at an exercise price of $1.10 for a period of five years from the closing date of the Offering. The Offering will provide gross proceeds to us of approximately $21.5 million. H.C. Wainwright & Co., LLC is acting as the sole lead placement agent for the offering in the United States and Canaccord Genuity Corp. is acting as co-placement agent for the offering in Canada.

The Offering is expected to close on or about December 12, 2014, subject to customary closing conditions, including the approval of the Toronto Stock Exchange and NYSE MKT to list for trading the shares issued in the offering or upon exercise of warrants. The warrants will not be separately listed for trading.

The Offering is being conducted in the United States only by means of a prospectus supplement and an accompanying prospectus filed as part of an effective shelf registration statement filed with the Securities and Exchange Commission ("SEC") on Form S-3 (File No. 333-200357), which was declared effective by the SEC on November 25, 2014. Copies of the prospectus supplement and accompanying prospectus, when available, can be obtained by request at H.C. Wainwright & Co., LLC by contacting by telephone at [phone] or by e-mail at [e-mail]. The offering will be made in Canada only by means of a Canadian MJDS prospectus supplement to the Canadian MJDS base shelf prospectus, dated November 28, 2014, filed with securities regulators in all the provinces of Canada, other than Quebec. The Canadian MJDS prospectus supplement will be, and the Canadian MJDS base shelf prospectus is, available on the Company's profile on www.sedar.com.

This announcement is neither an offer to sell nor a solicitation of an offer to buy any of Allied Nevada's common stock or warrants. No offer, solicitation or sale will be made in any jurisdiction in which such offer, solicitation or sale is unlawful.

Additional details of the Company's business, finances, appointments and agreements can be found as part of the Company's continuous public disclosure as a reporting issuer with the SEC and filed with Canadian securities regulators available at www.sec.gov and as filed on the Company's profile on www.sedar.com.

Cautionary Statement Regarding Forward Looking Information

This press release contains forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended (the "Securities Act"), Section 21E of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") (and the equivalent under Canadian securities laws) and the Private Securities Litigation Reform Act (the "PSLRA") or in releases made by the U.S. Securities and Exchange Commission (the "SEC"), all as may be amended from time to time. This cautionary statement is being made pursuant to the Securities Act, the Exchange Act and the PSLRA with the intention of obtaining the benefit of the "safe harbor" provisions of such laws.

All statements, other than statements of historical fact, included herein or incorporated by reference, that address activities, events or developments that we expect or anticipate will or may occur in the future, are forward-looking statements. Generally, these forward-looking statements can be identified by the use of forward-looking terminology such as "estimate", "plan", "anticipate", "expect", "intend", "believe", "project", "target", "budget", "may", "can", "will", "would", "could", "should", "seeks", or "scheduled to", or other similar words, or negatives of these terms or other variations of these terms or comparable language or any discussion of strategy or intentions. Such forward-looking statements include, without limitation, statements regarding our future business strategy, plans and goals; risks relating to fluctuations in the price of gold and silver; uncertainties concerning reserve, resource and grade estimates; the availability and timing of capital for financing the Company's exploration, development and expansion activities; anticipated costs, anticipated production, anticipated sales, anticipated capital expenditures, project economics, net present values and expected rates of return; the realization of expansion and construction activities and the timing thereof; production estimates and other statements that are not historical facts. Forward-looking statements address activities, events or developments that Allied Nevada expects or anticipates will or may occur in the future, and are based on current expectations and assumptions. These statements involve known and unknown risks, uncertainties, assumptions and other factors which may cause our actual results, performance or achievements to be materially different from any results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause actual results, performance or achievements to differ materially from those in the forward-looking statements include, among others, risks relating to fluctuations in the price of gold and silver; uncertainties concerning reserve, resource and grade estimates; the availability and timing of capital for financing the Company's exploration, development and expansion activities; anticipated costs, anticipated production, anticipated sales, anticipated capital expenditures, project economics, net present values and expected rates of return; the realization of expansion and construction activities and the timing thereof; production estimates; as well as those factors discussed in Allied Nevada's filings with the SEC including Allied Nevada's latest Annual Report on Form 10-K and its other SEC filings (and Canadian filings) including, without limitation, its latest Quarterly Report

on Form 10-Q (which may be secured from us, either directly or from our website at www.alliednevada.com or at the SEC website www.sec.gov). Although Allied Nevada has attempted to identify important factors that could cause actual results,

performance or achievements to differ materially from those described in forward-looking statements, there may be other factors that cause results, performance or achievements not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results, performance and achievements and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. The Company does not intend to publicly update any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required under applicable securities laws.

Contacts:
Allied Nevada Gold Corp.
Randy Buffington
President & CEO
[phone]

Allied Nevada Gold Corp.
Tracey Thom
Vice President, Investor Relations
[phone]



SOURCE: Allied Nevada Gold Corp.

[Wrinkles]

She'll be climbing sooooon Buddy!

[starbuxsux]

Heeeey Wrinks! Seems like that one did not have a bounce after the closing

$RMTI - Rockwell Medical Closes $58.5 Million Public Offering of Common Stock

1:26 PM ET 11/25/14 | GlobeNewswire

Rockwell Medical, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis, announced today the closing of the sale of 6,500,000 shares at $9.00 per share in an underwritten public offering for an aggregate offering amount of $58.5 million. The net proceeds from the offering, after commissions and other estimated offering expenses, were approximately $54.7 million. Rockwell has also granted the underwriters a 30-day option to purchase up to an additional 975,000 shares of common stock offered in the public offering.

The net proceeds of the offering will be used to repay outstanding secured indebtedness and for other general corporate purposes.

BofA Merrill Lynch is acting as the sole book-running manager for the proposed offering. Stifel is acting as Lead Manager and Summer Street Research Partners, Craig-Hallum Capital Group, Chardan Capital Markets, LLC and LifeSci Capital, LLC are acting as co-managers.

Shelf registration statements (File Nos. 333-181003 and 333-200379) relating to these securities were previously filed with, and declared effective by, the Securities and Exchange Commission. A prospectus supplement related to the offering was filed with the Securities and Exchange Commission on November 20, 2014. Copies of the prospectus supplement and accompanying prospectus relating to the offering may be obtained by contacting BofA Merrill Lynch, 222 Broadway, New York, NY 10038, Attn: Prospectus Department, or via email, at [e-mail]. An electronic copy of the final prospectus supplement and accompanying prospectus relating to the offering will be available on the website of the Securities and Exchange Commission at www.sec.gov.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities of Rockwell, and shall not constitute an offer, solicitation or sale of any security in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offer of these securities will be solely by means of a prospectus included in the registration statement and a prospectus supplement that will be issued in connection with the offering.

About Rockwell Medical

Rockwell Medical is a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis.

Rockwell's lead investigational drug Triferic is currently under NDA review by the FDA for the treatment of iron replacement and hemoglobin maintenance in dialysis patients, with a PDUFA date of January 24, 2015. Triferic delivers iron to dialysis patients during their regular dialysis treatment, using dialysate as the delivery mechanism.

Rockwell is preparing to launch its FDA approved generic drug Calcitriol, to treat secondary hyperparathyroidism in dialysis patients. Calcitriol (active vitamin D) injection is indicated in the management of hypocalcemia in patients undergoing chronic renal dialysis.

Rockwell is also an established manufacturer and leader in delivering high-quality hemodialysis concentrates/dialysates to dialysis providers and distributors in the U.S. and abroad.

Rockwell's exclusive renal drug therapies support disease management initiatives to improve the quality of life and care of dialysis patients and are intended to deliver safe and effective therapy, while decreasing drug administration costs and improving patient convenience. Rockwell Medical is developing a pipeline of drug therapies, including extensions of Triferic for indications outside of hemodialysis.

Triferic(TM) is a trademark of Rockwell Medical, Inc. / CitraPure(R) is a registered trademark of Rockwell Medical, Inc.

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws, including, but not limited to, Rockwell's intention to launch Calcitriol and SFP following FDA approval. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan", "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While Rockwell Medical believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in Rockwell Medical's SEC filings. Thus, actual results could be materially different. Rockwell Medical expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

CONTACT: Hans Vitzthum, Investor Relations; [phone]

http://www.globenewswire.com/newsroom/ti?nf=MTMjMTAxMDk5MTUjMzAzMTI=

[Wrinkles]

R.M.T.I. $8.30 area, double bottom on chart, has a PDUFA date late January and financing at $9 about to be completed anyday......great time to speculate I think, use stop if $8 breaks Buddy????

http://stockcharts.com/h-sc/ui?s=rmti

[JohnCM]

http://mmjbusinessdaily.com/investors-jump-at-australias-first-mj-public-offering/

[JohnCM]

Huge money grab ...

I have two companies I will be on the lookout for IPO but they are Canadian.

[starbuxsux]

$GPRO - GoPro announces pricing of follow-on public offering of 10,360,500 shares of its common stock at a price to the public of $75.00 per share by co and selling shareholders

2:26 AM ET 11/20/14 | Briefing.com

GoPro is offering 1,287,533 shares and the selling stockholders are offering 9,072,967 shares.

[starbuxsux]

$FOLD - Amicus Therapeutics Prices Underwritten Offering of Common Stock

7:15 PM ET 11/18/14 | GlobeNewswire

Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, today announced the pricing of an underwritten offering of 13,850,000 shares of its common stock at $6.50 per share. The gross proceeds from the offering to Amicus are expected to be $90.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Amicus. In addition, Amicus has granted the underwriters a 30-day option to purchase up to an additional 2,077,500 shares of its common stock. The offering is expected to close on November 24, 2014, subject to customary closing conditions.

J.P. Morgan Securities LLC is acting as sole book-running manager for the offering. Cowen and Company, LLC and Leerink Partners are acting as lead managers and Janney Montgomery Scott is acting as co-manager for the offering.

The Company expects to use the net proceeds of the offering for investment in the global commercialization infrastructure for migalastat monotherapy for Fabry disease, the continued clinical development of its product candidates and for other general corporate purposes.

The securities described above are being offered by Amicus pursuant to a registration statement previously filed and declared effective by the Securities and Exchange Commission (the "SEC"). A prospectus supplement relating to the offering will also be filed with the SEC. Copies of the prospectus supplement and accompanying base prospectus relating to the offering may be obtained by contacting J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717 (telephone number: 866-803-9204).

This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Amicus Therapeutics

Amicus Therapeutics (Nasdaq:FOLD) is a biopharmaceutical company at the forefront of therapies for rare and orphan diseases. The Company is developing novel, first-in-class treatments for a broad range of human genetic diseases, with a focus on delivering new benefits to individuals with lysosomal storage diseases. Amicus' lead programs include the small molecule pharmacological chaperones migalastat as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease; and AT2220 (duvoglustat) in combination with ERT for Pompe disease.

Forward-Looking Statements

Statements in this press release concerning Amicus' future expectations, plans and prospects, including, without limitation, statements regarding the proposed public offering, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements due to various risks, uncertainties and important factors, including those set forth in the "Risk Factors" section in the prospectus supplement relating to the offering and in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2013 filed with the Securities and Exchange Commission, any of which could cause its actual results to differ from those contained in the forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Amicus undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof.

FOLD-G

View data
CONTACT: Investors/Media: Amicus Therapeutics Sara Pellegrino Director, Investor Relations [e-mail] [phone] Media: Pure Communications Dan Budwick [e-mail] [phone]

http://www.globenewswire.com/newsroom/ti?nf=MTMjMTAxMDg5NDIjMTU5OTE=

[JohnCM]

w/k of 11/17/14 Paramount Group, Inc PGRE

Company
Business Profile
We are one of the largest vertically-integrated real estate companies focused on owning, operating and managing high-quality, Class A office properties in select central business district, or CBD, submarkets of New York City, Washington, D.C. and San Francisco. As of June 30, 2014, our portfolio consisted of 12 Class A office properties with an aggregate of approximately 10.4 million rentable square feet that was 90.7% leased to 253 tenants. Our New York City portfolio accounted for 75.5% of our annualized rent as of June 30, 2014, while our Washington, D.C. and San Francisco portfolios accounted for 11.3% and 13.2%, respectively. Our portfolio reflects our strategy, which has been consistent for nearly 20 years, of concentrating on select submarkets within leading gateway cities in the U.S. that have high barriers to entry, are supply constrained, exhibit strong economic characteristics and have a deep pool of prospective tenants in various industries with a strong demand for high-quality office space. Our properties are located in premier submarkets within midtown Manhattan, Washington, D.C. and San Francisco. Within these submarkets, our portfolio includes Class A office properties that are consistently among the most sought after addresses in the business community. As a result of the strong underlying fundamentals in our submarkets, the location and high-quality of our assets and our proven management capabilities, we believe that our portfolio is well positioned to provide continued cash flow growth and value creation.

Industry: Financials Founded: 1995 Employees: 217 Prospectus: Click Here Website: http://www.paramount-group.com Phone: [phone] Address:
1633 Broadway, Suite 1801, New York, NY 10019, US
- See more at: http://syndicatepro.com/company/PGRE/#sthash.mdIIz8eW.dpuf

[JohnCM]

Toronto based Pharmacan Capital ipo.

News?

[JohnCM]

[starbuxsux]

$NSPH - Nanosphere, Inc. Announces the Closing of Common Stock Offering

Oct 27, 2014 16:01:00 (ET)

Nanosphere, Inc. Announces the Closing of Common Stock Offering

NORTHBROOK, Ill., Oct. 27, 2014 (GLOBE NEWSWIRE) -- Nanosphere, Inc. (the "Company") (Nasdaq:NSPH), a company enhancing medicine through targeted molecular diagnostics, today announced the closing of its previously announced underwritten public offering of 40,000,000 shares of its common stock at a public offering price of $0.50 per share. As part of the fee payable to the underwriters in connection with the offering, the Company also issued 400,000 shares of common stock to the underwriters. Chardan Capital Markets, LLC acted as the sole book-running manager for the offering.

Net proceeds from the sale of the shares after underwriting discounts and commissions and other offering expenses are expected to be approximately $18.4 million. The Company plans to use the net proceeds from the offering for general corporate purposes and working capital.

The offering was made pursuant to a prospectus supplement to the Company's prospectus, dated October 22, 2014, filed as part of the Company's effective $100 million shelf registration statement. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

Copies of the final prospectus supplement and accompanying prospectus relating to these securities may be obtained by contacting Chardan Capital Markets, LLC, Attention: Scott Blakeman, Director of Operations, 17 State Street, Suite 1600, New York, NY or by telephone at 646-465-9000 or by email at [e-mail].

About the Verigene(R) System

The Verigene(R) System uses core proprietary gold nanoparticle chemistry to offer highly sensitive, highly specific molecular diagnostic results through low-cost multiplexing. The Verigene System rapidly and accurately detects infectious pathogens and drug resistance markers by mapping the genome of a particular bacterium. Currently, Verigene assays target infections of the bloodstream, respiratory tract and gastrointestinal tract. The System also offers additional capabilities in cancer, cardiovascular disease and autoimmune disease. The information gathered from Verigene enables clinicians to identify diseases earlier and make informed patient treatment decisions more quickly, which may result in improved patient outcomes, reduced costs, optimized antibiotic therapy, reduced spread of antibiotic resistance and saved lives.

About Nanosphere, Inc.

Nanosphere is enhancing medicine through targeted molecular diagnostics that result in earlier disease detection and enable optimal patient treatment and improved healthcare economics. The Company's versatile technology platform, the Verigene(R) System, allows clinicians to rapidly identify the most complex, costly and deadly infectious diseases through simple-to-use multiplexed diagnostic testing. The combination of this innovative technology and Nanosphere's customer-driven solutions keeps commitment to the patient at the forefront of its business. Nanosphere is based in Northbrook, IL. Additional information is available at http://www.nanosphere.us.

Forward Looking Statements

Except for historical information, the matters discussed in this press release are "forward-looking statements" and are subject to risks and uncertainties. Actual results could differ materially from these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the following: (i) Nanosphere's ability to develop commercially viable products; (ii) Nanosphere's ability to achieve profitability; (iii) Nanosphere's ability to produce and market its products; (iv) Nanosphere's ability to obtain regulatory approval of its products; (v) Nanosphere's ability to protect its intellectual property; (vi) competition and alternative technologies; and (vii) Nanosphere's ability to obtain additional financing to support its operations. Additional risks are discussed in the Company's current filings with the Securities and Exchange Commission. Although the Company believes the expectations reflected in such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. The forward-looking statements are made as of the date of this press release, and we undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

CONTACT: Investors:
Nanosphere, Inc.
Roger Moody, 847-400-9021
Chief Financial Officer
[e-mail]

or

Michael Rice
Founding Partner
LifeSci Advisors
646-587-6979
[e-mail]
(MORE TO FOLLOW) Dow Jones Newswires

October 27, 2014 16:01 ET (20:01 GMT)

[JohnCM]

BLOOM ENERGY ???

Bloom box ...

[TheMotivatedTrader]

IPO Watch: Roku wants to grow its media hub empire with a public stock filing - http://www.engadget.com/2014/10/25/roku-ipo-leak/

I have a Roku box and subscribe to the WWE Network. No disappointments here as the streaming quality is better than or equal regular cable (if using the standard A/V cables) or HD cable (using the HDMI input on the Roku).

[starbuxsux]

$TIVO - TiVo Announces Issuance of $230 Million 2% Convertible Senior Notes

8:30 AM ET 9/23/14 | Marketwire

TiVo Inc. (NASDAQ: TIVO) today announced the closing of its previously announced private offering of 2% Convertible Senior Notes due 2021. TiVo issued $230 million aggregate principal amount of notes, which included $30 million aggregate principal amount of notes issued pursuant to the full exercise of the initial purchasers' option to purchase additional notes to cover over-allotments. Additionally, TiVo has entered into convertible note hedge transactions with multiple counterparties, including certain of the initial purchasers and/or their affiliates (the "hedge counterparties"), and in connection therewith, TiVo has entered into separate privately negotiated warrant transactions with the hedge counterparties. TiVo expects that the combined impact of the notes offering and its previously announced intended use of proceeds to be anti-dilutive.

Barclays Capital Inc. and Deutsche Bank Securities Inc. acted as joint book-running managers for the notes offering. Nomura Securities International, Inc. and LionTree Advisors LLC acted as co-managers.

The notes are unsecured senior obligations of TiVo and bear interest at a rate of 2% per year payable semiannually in arrears on April 1 and October 1 of each year, beginning on April 1, 2015. The holders of the notes will have the ability to require TiVo to repurchase the notes in whole or in part for cash in the event of a fundamental change. In such case, the repurchase price would generally be 100% of the principal amount of the notes plus any accrued and unpaid interest. The notes are convertible into cash, shares of TiVo's common stock, or a combination of the two, at TiVo's election, at an initial conversion rate of 56.1073 shares per $1,000 principal amount of notes, equivalent to an initial conversion price of approximately $17.82 per share. Following certain corporate transactions that occur prior to the maturity date, TiVo will, in certain circumstances, increase the conversion rate for a holder that elects to convert its notes in connection with such a corporate transaction.

The net proceeds from the offering were approximately $223.5 million after deducting the initial purchasers' discounts and estimated offering expenses. TiVo used approximately $23.9 million of net proceeds to fund the cost of the convertible note hedge transactions (after such cost is partially offset by the proceeds of the warrant transactions). The combination of the note hedge and warrant transactions yield an effective conversion price of $24.00 per share, which is approximately 75% above the closing sale price of TiVo's common stock on September 16, 2014. TiVo also used approximately $41.8 million of net proceeds to fund the repurchase of common stock in privately negotiated transactions through one of the initial purchasers conducted concurrently with the pricing of the notes (the price per share of the common stock repurchased in such transactions was equal to the last reported sale price of TiVo's common stock on the Nasdaq Global Select Market on September 16, 2014, which equaled $13.71 per share of TiVo's common stock). TiVo intends to use the remaining net proceeds from the offering of the notes for general corporate purposes, including share repurchases that are expected to offset most of the potential dilution of TiVo's previously existing convertible debt. The repurchases funded by the proceeds of this offering are separate from TiVo's previously announced $350 million share repurchase program.

This announcement is neither an offer to sell nor a solicitation to buy any of these securities and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale is unlawful.

The notes and any common stock issuable upon conversion of the notes have not been registered under the Securities Act of 1933, as amended, or under any state securities laws and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These "forward-looking" statements include statements relating to, among other things, the expected use of the net proceeds. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, "believe," "expect," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. Factors that may cause actual results to differ materially include the conditions affecting the capital markets, general economic, industry, or political conditions, as well as the other potential factors described under "Risk Factors" in TiVo's public reports filed with the Securities and Exchange Commission, including TiVo's Annual Report on Form 10-K for the fiscal year ended January 31, 2014, Quarterly Reports on Form 10-Q for periods ended April 30, 2014 and July 31, 2014, and Current Reports on Form 8-K. TiVo cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. TiVo disclaims any obligation to update these forward-looking statements.

Contacts:
Investor Relations
Derrick Nueman
408-519-9677
[e-mail]

Media Relations
Joe McGurk
Sloane & Company
212-446-1874
[e-mail]



SOURCE: TiVo Inc.

[starbuxsux]

$BABA - TODAY, SEPTEMBER 19, 2014
11:28 AM ET Alibaba IPO Shares New Indicated Opening Range $92-$93
Dow Jones
11:27 AM ET Alibaba Group Holding (BABA) Ind: 80.00-83.00 Last 0.00
Dow Jones
11:22 AM ET U.S. Stocks Shoot Up to RecordsDow Jones
11:22 AM ET Alibaba IPO Shares New Indicated Opening Range $91-$92
Dow Jones
11:21 AM ET Alibaba Group Holding (BABA) Ind: 80.00-83.00 Last 0.00
Dow Jones
11:15 AM ET Alibaba.com indication now $90/91Briefing.com
11:14 AM ET Alibaba IPO Shares New Indicated Opening Range $90-$91
Dow Jones
11:14 AM ET UPDATE: Alibaba, quadruple-witching set to fire up the stock marketMarketWatch
11:13 AM ET Alibaba Group Holding (BABA) Ind: 80.00-83.00 Last 0.00
Dow Jones
11:09 AM ET Alibaba Shares Seen Heading for Big Gains Once Trading Starts
Dow Jones
11:04 AM ET Alibaba Group Holding (BABA) Ind: 80.00-83.00 Last 0.00
Dow Jones

[starbuxsux]

$TIVO - TiVo (TIVO) to Offer $200M Convertible Notes to Fund Share Repurchases

TiVo Inc. (NASDAQ: TIVO) announced today that it intends to offer, subject to market and other conditions, $200 million aggregate principal amount of Convertible Senior Notes due 2021 in a private offering. The notes will be offered only to qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933, as amended. TiVo also expects to grant the initial purchasers of the notes an over-allotment option to purchase up to an additional $30 million aggregate principal amount of notes.

TiVo intends to use the net proceeds from the offering of the notes (i) for general corporate purposes, including share repurchases representing up to 15.47 million shares (including the concurrent repurchase described in (ii) below), (ii) to fund the immediate repurchase of up to $50 million of common stock in privately negotiated transactions through one of the initial purchasers conducted concurrently with the pricing of the notes, and (iii) to fund the cost of convertible note hedge transactions (after such cost is partially offset by the proceeds that TiVo receives from entering into the warrant transactions) with certain hedge counterparties, as described below. Any repurchases funded by the proceeds of this offering are separate from TiVo's previously announced $350 million share repurchase program.

The notes will be convertible into cash, shares of TiVo's common stock, or a combination thereof, at TiVo's election. The interest rate, conversion rate and offering price are to be determined by negotiations between TiVo and the initial purchasers of the notes.

TiVo also expects to enter into convertible note hedge transactions with counterparties that may include the initial purchasers and/or their affiliates (the "hedge counterparties"). TiVo also intends to enter into separate privately negotiated warrant transactions with the hedge counterparties. These convertible note hedge transactions are expected to reduce the potential dilution with respect to TiVo's common stock upon conversion of the notes or offset any cash payments TiVo is required to make in excess of the principal amount of converted notes, as the case may be, upon any conversion of notes; however, the warrant transactions could have a dilutive effect with respect to TiVo's common stock to the extent that the market price per share of TiVo's common stock exceeds the strike price of the warrants. The effect, if any, of these activities on the market price of TiVo's common stock or the notes will depend on a variety of factors, including market conditions, and cannot be ascertained at this time.

TiVo has been advised that, in connection with establishing their initial hedge positions with respect to the convertible note hedge and warrant transactions, the hedge counterparties and/or their affiliates expect to purchase shares of TiVo's common stock or enter into various derivative transactions with respect to TiVo's common stock concurrently with, or shortly after, the pricing of the notes. These hedging activities could increase (or reduce the size of any decrease in) the market price of TiVo's common stock or the notes.

In addition, the hedge counterparties may modify their hedge positions (and are likely to do so during the conversion period related to any conversion of notes or following any repurchase of notes by TiVo on any fundamental repurchase date or otherwise) by entering into or unwinding various derivatives with respect to TiVo's common stock or purchasing or selling common stock or other securities of TiVo in secondary market transactions following the pricing of the notes and prior to the maturity of the notes.

[starbuxsux]

$SPEX - Spherix Files Mixed-Securities Shelf For Up to $30 Million >SPEX

Sep 15, 2014 17:24:00 (ET)


(MORE TO FOLLOW) Dow Jones Newswires (212-416-2800)

September 15, 2014 17:24 ET (21:24 GMT)


Copyright (c) 2014 Dow Jones & Company, Inc.

[starbuxsux]

$BABA - Alibaba Likely to Raise IPO Price Range, Sources Say

5:32 AM ET 9/15/14 | Dow Jones
By Prudence Ho

HONG KONG--Alibaba Group Holding Ltd. is likely to raise the price range of its U.S. initial public offering because of buoyant demand for the deal, people familiar with the situation said Monday.

It wasn't immediately clear what the new price range would be, but Alibaba would likely release the information in a filing with the U.S. Securities and Exchange Commission, they said.

Alibaba is seeking as much as US$24 billion in what could be the world's biggest ever IPO. The Chinese e-commerce major started the Asia leg of its roadshow Monday and is currently selling shares to investors in a range of US$60-US$66 apiece.

After Hong Kong, the next stop for Alibaba executives is Singapore, where they will host a lunch event and meetings with smaller groups of investors Tuesday. The roadshow, which began in New York on Sept. 8, is set to end Thursday.

Alibaba and its bankers have decided to close order books Tuesday for some U.S. investors and Wednesday for investors based in Asia and Europe, people familiar with the situation said earlier. However, investors in any country who haven't yet had their scheduled meeting with the company on its global roadshow will still be able to place orders once they have, the people added.

Alibaba plans to set a final price for the shares Thursday, with trading set to begin in New York the following day.

Telis Demos contributed to this article.

Write to Prudence Ho at [e-mail]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires



> Dow Jones Newswires

September 15, 2014 05:32 ET (09:32 GMT)

Copyright (c) 2014 Dow Jones & Company, Inc.

[starbuxsux]

$TWTR - Twitter announces $1.3 bln convertible unsecured senior note offering

4:24 PM ET 9/10/14 | Briefing.com

On September 10, 2014, Twitter, Inc. issued a press release announcing its intention to offer $650 million aggregate principal amount of convertible unsecured senior notes due 2019 and $650 million aggregate principal amount of convertible unsecured senior notes due 2021 in a private placement transaction to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. A copy of this press release is filed herewith as Exhibit 99.1 and is incorporated herein by reference.

[starbuxsux]

Citizens Financial Group Announces the Launch of an Initial Public Offering

PROVIDENCE, R.I., Sep 08, 2014 (BUSINESS WIRE) -- Citizens Financial Group, Inc. (Citizens) announced today the launch of an initial public offering of 140,000,000 shares, or 25%, of its common stock. The shares are being offered by The Royal Bank of Scotland Group plc at an initial offering price per share between $23 and $25. The selling shareholder has also granted a 30-day overallotment option of up to an additional 21,000,000 shares. The common stock has been approved to trade on the New York Stock Exchange under the symbol “CFG”. The offering is being made through global coordinators and joint book-running managers Morgan Stanley and Goldman, Sachs & Co and joint book runner J.P. Morgan.

Notes:

The prospectus relating to the offering may be obtained from: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, Second Floor, New York, New York 10014, via telephone: [phone] or via email: [e-mail]; Goldman Sachs & Co., Attention: Prospectus Department, 200 West Street, New York, New York 10282, via telephone: [phone] or via email: [e-mail]; and J.P. Morgan Securities LLC, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, via telephone: [phone]

The registration statement relating to these securities has been filed with the Securities and Exchange Commission, but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

About Citizens Financial Group, Inc.

Citizens Financial Group Inc. is one of the nation’s oldest and largest financial institutions, with $130.3 billion in assets as of June 30, 2014. Headquartered in Providence, Rhode Island, the company offers a broad range of retail and commercial banking products and services to individuals, small businesses, middle-market companies, large corporations and institutions. Consumer Banking helps its retail customers “bank better” with mobile and online banking, a 24/7 customer contact center and the convenience of approximately 3,200 ATMs and approximately 1,200 Citizens Bank and Charter One branches in 11 states in the New England, Mid-Atlantic and Midwest regions. Citizens also provides mortgage lending, auto lending, student lending and commercial banking services in selective markets nationwide. In Commercial Banking, Citizens offers corporate, institutional and not-for-profit clients a full range of wholesale banking products and services including lending and deposits, capital markets, treasury services, foreign exchange and interest hedging, leasing and asset finance, specialty finance and trade finance.

Citizens operates via subsidiaries Citizens Bank, N.A., and Citizens Bank of Pennsylvania. Additional information about Citizens and its full line of products and services can be found at www.citizensbank.com.

SOURCE: Citizens Financial Group, Inc.

Citizens Financial Group, Inc.
Investor Relations:
Ellen A. Taylor, 203-897-4240
[e-mail]
or
Media Relations:
Jim Hughes, 781-751-5404
[e-mail]

Copyright Business Wire 2014

[starbuxsux]

$BABA - Alibaba seeks to raise up to $24.3B in IPO record

Read more: http://www.cantondailyledger.com/article/20140905/News/140909468#ixzz3CwiV0XUl

[starbuxsux]

$PF - Pinnacle Foods falls 3.9% as Blackstone sells shares

7:35 AM ET 9/9/14 | MarketWatch

NEW YORK (Marketwatch) -- Shares of Pinnacle Foods Inc. (PF) fell 3.9% in premarket trade Tuesday after the packaged foods company said shareholders tied primarily to investment firm Blackstone will sell 15 million common shares. The sale, which will be completed through an underwritten secondary offering, will be completed Friday, the company said late Monday. Credit Suisse and Morgan Stanley are handling the deal.

-Ben Eisen; 415-439-6400; [e-mail]

> Dow Jones Newswires

September 09, 2014 07:35 ET (11:35 GMT)

Copyright (c) 2014 Dow Jones & Company, Inc.

[starbuxsux]

$ZBB - ZBB Energy Corporation Announces Successful Completion of Public Offering of Common Stock

11:50 AM ET 8/27/14 | Marketwire

ZBB Energy Corporation (NYSE MKT: ZBB) today announced that it has completed its previously announced underwritten public offering of common stock at a price to the public of $1.12 per share.

Due to the exercise in full of the underwriters' option to purchase additional shares of common stock, the company sold a total of 13,248,000 shares of its common stock in the offering for aggregate gross proceeds of approximately $14.8 million. ZBB Energy Corporation received approximately $13.5 million of net proceeds from the offering, after deducting the underwriting discount and estimated expenses of the offering payable by the company. Craig-Hallum Capital Group LLC acted as sole book-running manager for the offering.

A final prospectus supplement describing the terms of the offering has been filed with the SEC. Copies of the final prospectus supplement and the accompanying base prospectus may be obtained by contacting the book-running manager at the following address:

Craig-Hallum Capital Group LLC 222 South Ninth Street, Suite 350

Minneapolis, MN 55402 Telephone: [phone]

About ZBB Energy Corporation

ZBB Energy Corporation (NYSE MKT: ZBB) designs, develops, licenses and manufactures advanced energy storage and power electronics systems, as well as engineered custom and semi-custom products targeted at the growing global need for distributed renewable energy, energy efficiency, power quality, and grid modernization. ZBB's portfolio includes integrated power management platforms that combine advanced power and energy controls plus energy storage to optimize renewable energy sources and conventional power inputs for grid connected and off-grid applications. ZBB's innovative platforms solve a wide range of electrical system challenges in global markets for utility, governmental, commercial, industrial and residential customers. In addition, the platforms ensure optimal efficiencies today, while offering the flexibility to adapt and scale to future requirements. ZBB's corporate offices, engineering and development, and production facilities are located in Menomonee Falls, WI, USA with a research facility also located in Perth, Western Australia. ZBB has a joint venture with Meineng Energy, a provider of leading-edge energy storage systems and solutions to the greater China market. For more information, visit: www.zbbenergy.com.

Safe Harbor Statements

Certain statements made in this press release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended that are intended to be covered by the "safe harbor" created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "could," "seek," "intend," "plan," "estimate," "anticipate" or other comparable terms. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10-K and our subsequently filed Quarterly Reports on Form 10-Q. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

SOURCE: ZBB Energy Corporation

[JohnCM]

There was speculation 6 months ago that we might see something end of year or first quarter 2015.

[buccaneer1961]

that's an awesome oppty!!

[starbuxsux]

Alibaba's Revenue Growth Surges Before IPO

BY MICHAEL LIEDTKE
With what could be one of the largest IPO's ever on the horizon, Alibaba's revenue growth continued to climb rapidly last quarter.



Alibaba's quarterly revenue growth is surging again, a development that should help the Chinese e-commerce company sell its shares in what could be one of the world's largest IPOs.

The latest evidence of Alibaba's financial allure surfaced in a regulatory update filed Wednesday as the company prepares to complete its initial public offering of stock next month.

Alibaba's latest quarter ending June 30 was highlighted by revenue of $2.54 billion, a 46 percent increase from last year based on current exchange rates for the yuan.

The performance is likely to ease concerns that cropped up in June when Alibaba disclosed revenue growth of 39 percent during the quarter ending March 31, the slowest rate in six years.

Alibaba Holding Group Ltd. earned nearly $2 billion in the latest quarter, including a one-time gain of $1 billion generated by a reassessment of the company's investment portfolio.

If not for that accounting maneuver and other items unrelated to the company's ongoing business, Alibaba said it still would have earned nearly $1.2 billion. That represented a 60 percent increase in Alibaba's adjusted earnings from the previous year, according to the documents.

The impressive numbers set the stage for Alibaba's management to begin meeting after the Labor Day weekend with money managers interested in investing in the IPO. The roving presentations, known as a "road show," give investors a chance to gather more information while Alibaba's bankers gauge the demand for the company's stock before setting a price for the IPO shares and determining how many will be offered.

Analysts believe the demand to invest in Alibaba will be so intense that the company will be able to eclipse the $16 billion that Facebook Inc. raised two years ago. That IPO is the largest ever for a technology company. What's more, Alibaba is expected to debut on the New York Stock Exchange with a market value ranging $150 billion to $200 billion, topping all but a few U.S. companies.

Barring any hitches, the IPO should be completed by late September.

Alibaba is thriving because it has built an e-commerce bazaar that has become a shopping magnet for businesses and consumers alike as China's economy steadily grows. The company's network of sites includes Taobao, Tmall, and AliExpress, as well as Alibaba.

The total sales made on Alibaba's sites is now running at $296 billion annually, according to Wednesday's update, up from $248 billion annually when the company first filed its IPO documents in May. Alibaba now boasts 279 million active buyers, up from 231 million when the IPO process began.

In another promising sign as more online activity shifts away from personal computer, Alibaba attracts 188 million monthly visitors on mobile devices who are spending $71 billion annually, according to Wednesday's filing.

Alibaba isn't the only Internet company in line for a major windfall from the upcoming IPO.

Yahoo Inc. currently owns a 23 percent stake in Alibaba, and will whittle its holdings by selling 140 million shares in the IPO. The value of the Alibaba stake is the main reason that Yahoo's stock price has nearly tripled during the past two years, even as Yahoo has been struggling to boost its own revenue.



IMAGE: GETTY IMAGES
LAST UPDATED: AUG 28, 2014

[starbuxsux]

nothing...

[JohnCM]

BLOOM ENERGY ???

[starbuxsux]

$GRUB - GrubHub Files Registration Statement for Proposed Follow-On Offering of Common Stock

10:36 AM ET 8/25/14 | PR Newswire

GrubHub Inc. (the "Company") (NYSE: GRUB) announced today that it has publicly filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to a proposed follow-on public offering of its common stock. GrubHub Inc. is the nation's leading online and mobile food-ordering company dedicated to connecting hungry diners with local takeout restaurants. The GrubHub Inc. portfolio of brands includes GrubHub, Seamless, MenuPages and Allmenus.

Citigroup, Morgan Stanley and BofA Merrill Lynch will act as book-running managers for the proposed offering. Allen & Company LLC, BMO Capital Markets Corp., Canaccord Genuity Inc., Raymond James & Associates, Inc. and William Blair & Company, L.L.C. will act as co-managers for the proposed offering.

The proposed offering will be made only by means of a prospectus. A copy of the preliminary prospectus relating to these securities may be obtained when available from Citigroup, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by telephone at 1-800-831-9146; Morgan Stanley at Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014 or by telephone at 1-866-718-1649 and BofA Merrill Lynch at Attention: Prospectus Department, 222 Broadway, New York, NY 10038 or by e-mailing: [e-mail].

A registration statement relating to these securities has been filed with the U.S. Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the applicable securities laws of such state or jurisdiction.

The underwriters for the Company's April 2014 initial public offering have agreed to waive the lock-up restrictions to permit the Company and the selling stockholders to file this proposed registration on Form S-1 and to permit the Company to offer and sell shares. The lock-up restrictions will also be waived as to the selling stockholders immediately prior to the execution of the underwriting agreement to enable them to offer and sell shares in this proposed offering.

About GrubHub Inc.GrubHub Inc. is the nation's leading online and mobile food-ordering company dedicated to connecting hungry diners with local takeout restaurants. The GrubHub Inc. portfolio of brands includes GrubHub, Seamless, MenuPages and Allmenus. The Company's online and mobile ordering platforms allow diners to order directly from more than 30,000 takeout restaurants in more than 700 U.S. cities and London, and every order is supported by the Company's 24/7 customer service. GrubHub Inc. has offices in Chicago, New York City and London.

Contacts:Investor Relations:Anan Kashyap, GrubHub Inc.Email: [e-mail]

Media Relations:Meghan Gage, GrubHub Inc.Phone: [phone]Email: [e-mail]

SOURCE GrubHub Inc.

[starbuxsux]

$USEL - uSell.com Prices $4.65 Million Registered Direct Offering

7:31 AM ET 8/12/14 | Marketwire

uSell.com, Inc. (OTCQB: USEL), a leading US-based reCommerce marketplace that instantly finds cash offers for used smartphones and electronics, announced today that it has priced a registered direct public offering of units consisting of one share of common stock and a warrant to purchase one-half share of common stock. The common stock and warrants will separate immediately. Dawson James Securities, Inc. is acting as the exclusive placement agent for the offering on a best efforts basis.

The units are being offered at a price of $3.00 per unit. The warrants have a term of five years and an exercise price of $3.20 per warrant share. The gross proceeds to uSell.com from this offering are expected to be approximately $4,650,000, before deducting placement agent commissions and estimated offering expenses. The Company expects to close the offering on Friday August 15, 2014, subject to customary closing conditions.

uSell.com intends to use the net proceeds from this offering for marketing, improvements in its platform technology and working capital.

A registration statement relating to the shares of common stock and warrants to be issued in the offering has been filed with the Securities and Exchange Commission ("SEC") and is effective. A final prospectus relating to the offering will be filed with the SEC. Electronic copies of the final prospectus will also be available on the SEC website at http://www.sec.gov. Copies of the final prospectus may be obtained, when available, from the offices of Dawson James Securities, 1 North Federal Highway, Suite 500, Boca Raton, FL 33432, telephone: [phone].

This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted.

About uSell.com, Inc. uSell.com is a reCommerce marketplace that helps individuals turn unused items into cash. uSell ensures that customers get the highest payouts with the least amount of hassle by facilitating risk-free transactions with professional buyers. For uSell's buyers, uSell offers a scalable technology, marketing, logistics, and analytics solution that provides a high volume of inventory at a low acquisition cost.

Forward-Looking Statements When used in this release, the word "expects" and similar expressions are intended to identify forward-looking statements. Forward-looking statements include, without limitation, uSell's ability to complete the proposed public offering of its common stock and warrants described above. Such statements are subject to risks and uncertainties which could cause actual results to differ materially from those projected. uSell undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Contact Information
Hayden IR
[e-mail]
917-658-7878



SOURCE: uSell.com

[buccaneer1961]

oh,ok,thankyou

[starbuxsux]

Not sure you can...I woukd ask your broker if they have shares...otherwise it's grab what you can at the open.